Clinical significance of baseline Epstein-Barr virus DNA for recurrent or metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Future Oncol
; 19(37): 2481-2492, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-38054449
ABSTRACT
Background:
This study aimed to evaluate the clinical significance of baseline Epstein-Barr virus (EBV) DNA in recurrent or metastatic primary pulmonary lymphoepithelioma-like carcinoma (PLELC).Methods:
75 patients with baseline EBV DNA were included. The relationships between baseline EBV DNA and clinical characteristics, survival and objective response rate were analyzed.Results:
The baseline EBV DNA levels were related to the liver, chest wall, distant lymph node(s) or multiple sites of distant metastasis. The high baseline EBV DNA group (≥41,900 copies/ml) was related to shorter progression-free and overall survival in univariate analysis and remained significant for progression-free survival in multivariate analysis.Conclusion:
The baseline EBV DNA is a valuable biomarker for predicting prognosis and reflecting tumor burden in recurrent or metastatic PLELC.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Neoplasias Nasofaríngeas
/
Infecciones por Virus de Epstein-Barr
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
China